This brand name is authorized in Austria, Australia, Brazil, Canada, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, United States
The drug BAVENCIO contains one active pharmaceutical ingredient (API):
1
Avelumab
UNII KXG2PJ551I - AVELUMAB
|
Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab binds PD-L1 and blocks the interaction between PD-L1 and the programmed death 1 (PD-1) and B7.1 receptors. This removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell responses. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
BAVENCIO Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
L01FF04 | Avelumab | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 11671G, 11679Q, 11685B, 11695M |
Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 525418100050401 |
Country: CA | Health Products and Food Branch | Identifier(s): 02469723 |
Country: EE | Ravimiamet | Identifier(s): 1753275 |
Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 1171214001 |
Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 480316 |
Country: FR | Base de données publique des médicaments | Identifier(s): 60199966 |
Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 348648 |
Country: HK | Department of Health Drug Office | Identifier(s): 65956 |
Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 8147 |
Country: JP | 医薬品医療機器総合機構 | Identifier(s): 4291438A1022 |
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1083944 |
Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 148008 |
Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100400386 |
Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W65131001 |
Country: SG | Health Sciences Authority | Identifier(s): 15672P |
Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699808770134 |
Country: US | FDA, National Drug Code | Identifier(s): 44087-3535 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.